FAQ: Clene Inc. Presentation at H.C. Wainwright Global Investment Conference

What is the main announcement in this content?

Clene Inc. announced that its management will present at the H.C. Wainwright 27th Annual Global Investment Conference and host one-on-one investor meetings.

Where can I find the full press release about this announcement?

The full press release can be viewed at https://ibn.fm/d4eRn.

What type of company is Clene Inc.?

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.

What diseases does Clene Inc. focus on treating?

The company focuses on treating neurodegenerative diseases including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.

What is CNM-Au8® and what does it do?

CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress.

Where is Clene Inc. based and where are its operations located?

The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.

How can I get the latest news and updates about Clene Inc.?

The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN.

What is BioMedWire and what services do they provide?

BioMedWire is a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences that provides wire solutions, editorial syndication, press release enhancement, social media distribution, and corporate communications solutions.